Lumida
/DH
⌘K
Definitive Healthcare Corp

Definitive Healthcare Corp

DH
$0.76USD↓-7.57%-0.06 today

MARKET CAP

109.1M

P/E (TTM)

2.9x

FWD P/E

4.1x

DAY RANGE

$1 – $1

52W RANGE

$1
$5

AI Summary

Stalk
Buy NowMedium

In early Stage 1 consolidation off a terminal downtrend, DH is exhibiting initial repair signals via a Momentum Breakout clearing the base high and support at the 9/21 EMAs. Oversold context and a Bullish Pivot Point signal mean downside control has failed, favoring medium-term bullish participation. Execution now is appropriate on minor pullbacks into the EMA cluster or the base breakout zone. Key risks include a rejection at the flat-to-down 50-day SMA and failure to hold EMA support, which would invalidate the repair phase.

  • ↑Launched 60+ new data integrations, boosting client stickiness.
  • ↑Professional services revenue grew 49% YoY, driving upsell.
  • ↓Q1’26 guidance of $54–56M and FY’26 at $220–226M (-6% to ‑9% YoY).
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Definitive Healthcare Corp. (NASDAQ: DH) is a provider of data and analytics solutions focused on the healthcare sector, offering insights into healthcare providers, patients, and the operational landscape. The company specializes in delivering differentiated data, emphasizing integration and customer engagement to optimize healthcare operations, particularly for clients in life sciences. Positioned at the convergence of healthcare technology and data analytics, Definitive Healthcare serves a critical role in enhancing commercial intelligence for its healthcare clients amidst evolving market dynamics.

Bull says

  • ↑Launched 60+ new data integrations, boosting client stickiness.
  • ↑Professional services revenue grew 49% YoY, driving upsell.
  • ↑Generated $67.1M unlevered FCF (91% of adj. EBITDA).
  • ↑AI-enabled product updates due in 2025 to preserve margins.
  • ↑High earnings yield and 2.7x book-to-price signal deep value.
  • ↑Mgmt expects NDR bottom in 2025, rising in 2026.

Bear says

  • ↓Q1’26 guidance of $54–56M and FY’26 at $220–226M (-6% to ‑9% YoY).
  • ↓Fixed cost base risks negative operating leverage on revenue declines.
  • ↓Stock volatility is high, and momentum factors remain weak.
  • ↓Negative leverage and weak profitability factors raise financial risk.
  • ↓Elevated short interest and recent rating cuts underscore skepticism.
  • ↓Net dollar retention pressured through 2025 before expected recovery.

Investment themes with DH

Buybacks↑ +0.48%

Companies repurchasing their own shares

C · JCI · WFC

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 02-28-2026neutral

Transcript signals

Bull points

  • And as we look at the business from a cohort perspective, the first cohort of renewals, excluding the first quarter of 24, where the disruption occurred, was posted this last quarter in Q4. And that performance on a business-sold post-Q1 24 basis and up for renewal through 2025 shows about a 200 basis points improvement over the previous comparison quarters, even extending back to 22.
  • So we're seeing the integration focus starting to accelerate. Our commercial teams are promoting that because it's good for the customer, as well as good for us. And we're very confident that that performance in the fourth quarter, which often is a more difficult quarter to get moving, was actually very positive, especially in comparison to the full year.
  • we are in a much stronger position. We've remediated the claims data disruption by bringing on a new data source late in 25. We've got an additional data source ready to come online in the next couple of weeks as well to further add to our claims volumes. And Kevin touched on some of the additional new data that we've added into product as well, plus just more broadly restarting our overall product innovation engine. So we've got a lot more tools in the kit, essentially, as we stand here at the start of 2026 than we did at the start of 2025.

Bear points

  • when you have, say, 30% of records that suddenly evaporate from the market, and if you've entitled your customers to expect a certain number of records, and now there's 30% less, regardless of the reason, there's going to be pressure on right-sizing and down-sell pressure when you renew, or they want to be made right.
  • that's what we're really focused around kind of executing against while continuing to nurture the growth that we're seeing within diversified in the provider space.
  • we really just have these downsell pressures throughout, you know, 24 and 25 as a result of claims data disruption.
Read full transcript analysis ›